Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0043-1777040
Case Report with Review of Literature

Clinical Outcomes of Crizotinib Readministration in Patients with Nonsmall Cell Lung Cancer with Anaplastic Lymphoma Kinase Rearrangement: Case Report and Review of Literature

Prasant Kumar Parida
1   Department of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India
› Author Affiliations Funding This study was supported by Department of Medical Oncology, Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Recent studies have demonstrated promising outcomes of the first-line anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) “crizotinib” in patients with locally advanced and metastatic lung cancers with high expression of the fusion protein “EML4-ALK.” High drug resistance, however, restricts the therapeutic advantages of ALK-TKIs in patients with nonsmall cell lung cancer (NSCLC). The contemporary literature documents limited treatment approaches for patients with NSCLC relapse or nonresponsiveness to second-/third-generation ALK-TKIs. We hereby provide a descriptive analysis of five NSCLC cases treated with crizotinib, ceritinib, and alectinib for a median duration of 54 months. The outcomes indicate a profound therapeutic response in patients receiving 4th and subsequent line of treatment with crizotinib. The crizotinib retreatment actively reduced patient resistance to the ALK-TKIs by reversing the mesenchymal epithelial transition amplification. The results from this case series also emphasize the possible role of next-generation sequencing in determining therapeutic resistance and transforming the treatment paradigm for NSCLC. Partial response was observed in the patients after 6 months of crizotinib readministration. This is possibly the first case series reporting crizotinib rechallenge in patients of ALK positive NSCLC who failed on subsequent ALK-TKIs and multiple lines of chemotherapies.

Keywords

NSCLC - lung cancer - EML4-ALK - ALKi

Patient Consent

The author certifies that he has obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/ her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.


Financial Support and Sponsorship

None.




Publication History

Article published online:
28 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Soda M, Choi YL, Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153) 561-566
    CrossrefPubMedSearch in Google Scholar
  • 2 Shaw AT, Yeap BY, Mino-Kenudson M. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27 (26) 4247-4253
    CrossrefPubMedSearch in Google Scholar
  • 3 Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018; 17 (01) 52
    CrossrefPubMedSearch in Google Scholar
  • 4 Shaw AT, Kim D-W, Nakagawa K. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedSearch in Google Scholar
  • 5 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017; 7 (02) 137-155
    CrossrefPubMedSearch in Google Scholar
  • 6 Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015; 21 (10) 2227-2235
    CrossrefPubMedSearch in Google Scholar
  • 7 Gainor JF, Dardaei L, Yoda S. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016; 6 (10) 1118-1133
    CrossrefPubMedSearch in Google Scholar
  • 8 Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book 2019; 39 (39) 531-542
    CrossrefPubMedSearch in Google Scholar
  • 9 Gouji T, Takashi S, Mitsuhiro T, Yukito I. Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?. J Thorac Oncol 2014; 9 (03) e27-e28
    CrossrefPubMedSearch in Google Scholar
  • 10 Gettinger SN, Bazhenova LA, Langer CJ. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016; 17 (12) 1683-1696
    CrossrefPubMedSearch in Google Scholar
  • 11 Basit S, Ashraf Z, Lee K, Latif M. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem 2017; 134: 348-356
    CrossrefPubMedSearch in Google Scholar
  • 12 Zou HY, Friboulet L, Kodack DP. et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 2015; 28 (01) 70-81
    CrossrefPubMedSearch in Google Scholar
  • 13 Friboulet L, Li N, Katayama R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4 (06) 662-673
    CrossrefPubMedSearch in Google Scholar
  • 14 Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci 2018; 109 (03) 572-580
    CrossrefPubMedSearch in Google Scholar
  • 15 Shaw AT, Friboulet L, Leshchiner I. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016; 374 (01) 54-61
    CrossrefPubMedSearch in Google Scholar
  • 16 Sakakibara-Konishi J, Kitai H, Ikezawa Y. et al. Response to crizotinib re-administration after progression on lorlatinib in a patient with ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer 2019; 20 (05) e555-e559
    CrossrefPubMedSearch in Google Scholar
  • 17 Becker A, Crombag L, Heideman DA. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011; 47 (17) 2603-2606
    CrossrefPubMedSearch in Google Scholar
  • 18 Schrödl K, von Schilling C, Tufman A, Huber RM, Gamarra F. Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. Respiration 2014; 88 (03) 262-264
    CrossrefPubMedSearch in Google Scholar
  • 19 Sánchez-Herrero E, Serna-Blasco R, Ivanchuk V. et al. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Mol Oncol 2021; 15 (09) 2363-2376
    CrossrefPubMedSearch in Google Scholar
  • 20 Lindeman NI, Cagle PT, Beasley MB. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8 (07) 823-859
    CrossrefPubMedSearch in Google Scholar
  • 21 Sánchez-Herrero E, Blanco Clemente M, Calvo V, Provencio M, Romero A. Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report. Transl Lung Cancer Res 2020; 9 (02) 366-372
    CrossrefPubMedSearch in Google Scholar